3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.
Yassir Younis, Frederic Douelle, Tzu-Shean Feng, Diego González Cabrera, Claire Le Manach, Aloysius T Nchinda, Sandra Duffy, Karen L White, David M Shackleford, Julia Morizzi, Janne Mannila, Kasiram Katneni, Ravi Bhamidipati, K Mohammed Zabiulla, Jayan T Joseph, Sridevi Bashyam, David Waterson, Michael J Witty, David Hardick, Sergio Wittlin, Vicky Avery, Susan A Charman, Kelly Chibale
文献索引:J. Med. Chem. 7th ed., 55 , 3479-3487, (2012)
全文:HTML全文
摘要
A novel class of orally active antimalarial 3,5-diaryl-2-aminopyridines has been identified from phenotypic whole cell high-throughput screening of a commercially available SoftFocus kinase library. The compounds were evaluated in vitro for their antiplasmodial activity against K1 (chloroquine and drug-resistant strain) and NF54 (chloroquine-susceptible strain) as well as for their cytotoxicity. Synthesis and structure-activity studies identified a number of promising compounds with selective antiplasmodial activity. One of these frontrunner compounds, 15, was equipotent across the two strains (K1 = 25.0 nM, NF54 = 28.0 nM) and superior to chloroquine in the K1 strain (chloroquine IC(50) K1 = 194.0 nM). Compound 15 completely cured Plasmodium berghei-infected mice with a single oral dose of 30 mg/kg. Dose-response studies generated ED(50) and ED(90) values of 0.83 and 1.74 mg/kg for 15 in the standard four-dose Peters test. Pharmacokinetic studies in the rat indicated that this compound has good oral bioavailability (51% at 20 mg/kg) and a reasonable half-life (t(1/2) ∼ 7-8 h).© 2012 American Chemical Society
相关化合物
相关文献:
2012-03-05
[Angew. Chem. Int. Ed. Engl. 10th ed., 51 , 2492-2495, (2012)]
2011-10-21
[J. Org. Chem. 76 , 8203-8214, (2011)]
2011-11-01
[Eur. J. Med. Chem. 11th ed., 46 , 5416-5434, (2011)]
2007-11-09
[J. Org. Chem. 72 , 8870, (2007)]
2012-01-01
[Bioorg. Med. Chem. 1st ed., 20 , 467-479, (2012)]